KRAS and ovarian carcinoma: It was found that CB-839 could synergize with other anticancer drugs to exert beneficial therapeutic effects, and KRAS mutation led to enhanced glucose and glutamine metabolism in ovarian cancer cells, which was better inhibited by the combination of metformin and CB-839 [32].